Detailed Information on Publication Record
2021
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up
ROMŽOVÁ, Marianna, Dagmar SMITALOVÁ, Jakub HYNŠT, Nikola TOM, Tomáš LOJA et. al.Basic information
Original name
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up
Authors
ROMŽOVÁ, Marianna (703 Slovakia, guarantor, belonging to the institution), Dagmar SMITALOVÁ (203 Czech Republic, belonging to the institution), Jakub HYNŠT (203 Czech Republic, belonging to the institution), Nikola TOM (203 Czech Republic, belonging to the institution), Tomáš LOJA (703 Slovakia, belonging to the institution), Zdeňka HERUDKOVÁ (203 Czech Republic, belonging to the institution), Tomáš JURČEK (203 Czech Republic), Lukas STEJSKAL (203 Czech Republic), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic) and Martin ČULEN (703 Slovakia, belonging to the institution)
Edition
British journal of haematology, Hoboken, Wiley-Blackwell, 2021, 0007-1048
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 8.615
RIV identification code
RIV/00216224:14740/21:00120115
Organization unit
Central European Institute of Technology
UT WoS
000668741700001
Keywords in English
CML; NGS; progenitors; leukaemic stem cells; somatic mutations; ASXL1
Tags
International impact, Reviewed
Změněno: 15/10/2024 14:08, Ing. Martina Blahová
Abstract
V originále
There is an emerging body of evidence that patients with chronic myeloid leukaemia (CML) may carry not only breakpoint cluster region-Abelson murine leukaemia viral oncogene homologue 1 (BCR-ABL1) kinase domain mutations (BCR-ABL1 KD mutations), but also mutations in other genes. Their occurrence is highest during progression or at failure, but their impact at diagnosis is unclear. In the present study, we prospectively screened for mutations in 18 myeloid neoplasm-associated genes and BCR-ABL1 KD in the following populations: bulk leucocytes, CD34(+)CD38(+) progenitors and CD34(+)CD38(-) stem cells, at diagnosis and early follow-up. In our cohort of chronic phase CML patients, nine of 49 patients harboured somatic mutations in the following genes: six ASXL1 mutations, one SETBP1, one TP53, one JAK2, but no BCR-ABL1 KD mutations. In seven of the nine patients, mutations were detected in multiple hierarchical populations including bulk leucocytes at diagnosis. The mutation dynamics reflected the BCR-ABL1 transcript decline induced by treatment in eight of the nine cases, suggesting that mutations were acquired in the Philadelphia chromosome (Ph)-positive clone. In one patient, the JAK2 V617F mutation correlated with a concomitant Ph-negative myeloproliferative neoplasm and persisted despite a 5-log reduction of the BCR-ABL1 transcript. Only two of the nine patients with mutations failed first-line therapy. No correlation was found between the mutation status and survival or response outcomes.
Links
MUNI/A/1595/2020, interní kód MU |
| ||
NV17-30397A, research and development project |
| ||
90132, large research infrastructures |
|